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In Reply On behalf of the PD REHAB Collaborative Group, we are pleased that the 
PD REHAB Trial1 has prompted debate. The issues raised are common to the 3 
letters2- 4 and all were covered in the original article.1 
 
Eligibility was based on the uncertainty principle. Investigators were mostly uncertain 
of the value of physiotherapy and occupational therapy in patients with mild to 
moderate Parkinson disease (PD). So, the results of the trial can only be applied to 
patients with mild to moderate disease. This is not in conflict with our Cochrane 
review of physical therapies in PD, which showed short-term benefits in motor 
function and activities of daily living but, importantly, not in quality of life in more 
severe disease.5 
 
The Nottingham Extended Activities of Daily Living Scale was used as the primary 
outcome so that any benefits could be compared with those in other disease areas 
where it has been used before (ie, stroke and aging). It has been used in previous 
PD trials and correlated well with the Unified Parkinson’s Disease Rating Scale 
activities of daily living scale in our pilot PD/OT trial.6 This approach precluded the 
use of an individualized outcome as suggested by de Vries et al4 in their letter. 
Although the Nottingham Extended Activities of Daily Living Scale does not directly 
address gait and transfers, it does assess issues such as walking outside, using 
public transport, and climbing stairs, which are of more practical use and more 
important to patients. Indeed, our patient advisory group supported the use of the 
Nottingham Extended Activities of Daily Living as the primary outcome for this very 
reason. 
 
We too were surprised by the low dose of both therapies, but this is what is being 
delivered to patients with mild to moderate PD in the National Health Service (NHS) 
today. We do not agree with Mestriner3 that this is nonadherence; it is a low-dose 
intervention. We were informed by therapists before the trial that both 
physiotherapists and occupational therapists see such referrals, so they wanted the 
combined design of the PD REHAB Trial. A large number of centers were 
deliberately secured to aid recruitment and to ensure that the results could be 
generalized across the NHS. Therefore, PD REHAB is a pragmatic trial of standard 
care in the NHS and not a study of a novel high-intensity form of therapy. This is the 
design that the funder, the NHS Health Technology Assessment Programme, 
wanted to inform decisions to be made about the future delivery of such services 
within the NHS. 
 
The PD REHAB Trial is a high-quality, precise, adequately powered study that 
demonstrates that low-dose, patient-centered, goal-directed physiotherapy and 
occupational therapy in early PD is ineffective. We cannot ignore or seek to discredit 
important results that we do not find palatable. We owe it to our patients to deliver 
the best care possible, so future research should explore the development and 
testing of more structured and intensive physical and occupational therapy programs 
in patients with all stages of PD. 
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